Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRESENT
- Sponsors Galena Biopharma
- 09 Nov 2016 According to a Galena Biopharma media release, management will present the top-line data from the trial and its assessment of the results in conference call.
- 09 Aug 2016 Company has initiated an investigation into the causes of the the Independent Data Monitoring Committee (IDMC) recommendation to stop the trial, according to a Galena Biopharma media release.
- 09 Aug 2016 Company has shared the PRESENT trial information with the investigators of two other trials (see profile 210321 and 243798) and these trial will continue as as planned, according to a Galena Biopharma media release.